Quoin Pharmaceuticals Files 8-K on Shareholder Nominations
Ticker: QNRX · Form: 8-K · Filed: Sep 30, 2024 · CIK: 1671502
| Field | Detail |
|---|---|
| Company | Quoin Pharmaceuticals, Ltd. (QNRX) |
| Form Type | 8-K |
| Filed Date | Sep 30, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, filing-update
TL;DR
Quoin Pharma filed an 8-K for shareholder nominations - board changes incoming?
AI Summary
Quoin Pharmaceuticals, Ltd. filed an 8-K on September 30, 2024, reporting on shareholder nominations pursuant to Exchange Act Rule 14a-11 and other events. The filing date is September 27, 2024. The company was formerly known as Cellect Biotechnology Ltd. and Cellect Biomed Ltd.
Why It Matters
This filing indicates potential changes or discussions regarding the company's board composition, which could impact its strategic direction and governance.
Risk Assessment
Risk Level: medium — Filings related to shareholder nominations and potential board changes can introduce uncertainty and signal potential shifts in company strategy.
Key Players & Entities
- Quoin Pharmaceuticals, Ltd. (company) — Registrant
- Cellect Biotechnology Ltd. (company) — Former company name
- Cellect Biomed Ltd. (company) — Former company name
- September 27, 2024 (date) — Earliest event reported date
- September 30, 2024 (date) — Filing date
FAQ
What specific events are being reported under 'Other Events' in this 8-K filing?
The filing explicitly mentions 'Shareholder Nominations Pursuant to Exchange Act Rule 14a-11' and 'Other Events' as items of disclosure, but the specific details of the 'Other Events' are not elaborated in the provided header information.
When was Quoin Pharmaceuticals, Ltd. previously known by other names?
The company was formerly known as Cellect Biotechnology Ltd. as of July 21, 2016, and prior to that, as Cellect Biomed Ltd. as of April 6, 2016.
What is the principal executive office address for Quoin Pharmaceuticals, Ltd.?
The principal executive offices are located at 42127 Pleasant Forest Court, Ashburn, VA 20148-7349.
What is the SIC code for Quoin Pharmaceuticals, Ltd.?
The Standard Industrial Classification (SIC) code for Quoin Pharmaceuticals, Ltd. is 2834, which corresponds to Pharmaceutical Preparations.
What is the filing date and the date of the earliest event reported for this 8-K?
The 8-K was filed on September 30, 2024, and the date of the earliest event reported is September 27, 2024.
Filing Stats: 710 words · 3 min read · ~2 pages · Grade level 12.4 · Accepted 2024-09-30 06:07:42
Filing Documents
- tm2425163d1_8k.htm (8-K) — 27KB
- 0001104659-24-103867.txt ( ) — 195KB
- qnrx-20240927_lab.xml (EX-101.LAB) — 33KB
- qnrx-20240927_pre.xml (EX-101.PRE) — 22KB
- qnrx-20240927.xsd (EX-101.SCH) — 3KB
- tm2425163d1_8k_htm.xml (XML) — 4KB
08 Shareholder
Item 5.08 Shareholder Director Nominations. To the extent applicable, the information in Item 8.01 of this Current Report on Form 8-K is incorporated by reference into this Item 5.08.
01. Other Events
Item 8.01. Other Events. On September 27, 2024, the Board of Directors (the "Board") of Quoin Pharmaceuticals Ltd. (the "Company") set the meeting date for the 2024 Annual General Meeting of Shareholders ("2024 AGM"), as December 5, 2024. Because the scheduled date of the 2024 AGM is more than 30 days after the anniversary of the Company's 2023 Annual General Meeting of Shareholders, the Company is filing this Current Report on Form 8-K to provide notice of certain revised deadlines for the submission of shareholder proposals in connection with the 2024 AGM. Because the scheduled date of the 2024 AGM is more than 30 days after the anniversary of the Company's 2023 Annual General Meeting of Shareholders, prior disclosed deadlines regarding the submission of shareholder proposals pursuant to Rule 14a-8 ("Rule 14a-8") under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), for the 2024 AGM are no longer applicable. In order for a shareholder proposal, submitted pursuant to Rule 14a-8, to be considered timely for inclusion in the Company's proxy statement and form of proxy for the 2024 AGM, such proposal must be received by the Company by October 10, 2024. The Company has determined that October 10, 2024 is a reasonable time before the Company plans to begin printing and mailing its proxy materials. In addition, to comply with the universal proxy rules, shareholders who intend to solicit proxies in support of director nominees other than our nominees must provide notice that sets forth the information required by Rule 14a-19 under the Exchange Act by October 10, 2024, the tenth calendar day following the date of this Current Report on Form 8-K publicly announcing the date of the 2024 AGM.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. Date: September 30, 2024 QUOIN PHARMACEUTICALS LTD. By: /s/ Gordon Dunn Name: Gordon Dunn Title: Chief Financial Officer